



Corrigendum

Corrigendum to “Considerations for the Treatment of Oesophageal Cancer with Radiotherapy During the COVID-19 Pandemic” [Clin Oncol 32 (2020) 354–357]



C.M. Jones^{*†‡}, M. Hawkins[§], S. Mukherjee[¶], G. Radhakrishna^{||}, T. Crosby^{**}

^{*} School of Molecular & Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, UK

[†] Radiotherapy Research Group, Leeds Institute of Medical Research at St James's, Faculty of Medicine & Health, University of Leeds, Leeds, UK

[‡] Leeds Cancer Centre, The Leeds Teaching Hospitals NHS Trust, Leeds, UK

[§] Department of Medical Physics & Biomedical Engineering, University College London, London, UK

[¶] CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK

^{||} Christie Hospital, The Christie NHS Foundation Trust, Manchester, UK

^{**} Velindre Cancer Centre, Cardiff, UK

The author regrets that in Table 1 of this manuscript, the suggested dose for hypofractionated radiotherapy was erroneously described as 55 Gy/10 fractions for tumours of up to 10cm in length. In keeping with the main text of the article, which is correct, this should have described a recommended dose of 50–55 Gy/20 fractions.

DOI of original article: <https://doi.org/10.1016/j.clon.2020.04.001>.

Author for correspondence: T. Crosby, Velindre Cancer Centre, Velindre Road, Whitchurch, Cardiff CF14 2TL, UK. Tel: +44-29-2061-5888.

E-mail address: tom.crosby@wales.nhs.uk (T. Crosby).

<https://doi.org/10.1016/j.clon.2021.03.010>

0936-6555/© 2020 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.